Researchers recently conducted a multicenter observational cohort study to examine the condition severity and the clinical outcomes of patients with different Clostridium difficile strains. The ...
Am J Health Syst Pharm. 2012;69(11):933-943. Based on current clinical trials reporting fewer recurrences among patients treated with fidaxomicin in which the non-NAP1/BI/027 strains were isolated, ...
ve genetic regions have been identified that are unique to the most virulent strain of Clostridium difficile (C. difficile), the hospital superbug. Researchers writing in BioMed Central's open access ...
SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the top-line results from its second fidaxomicin Phase 3 ...
In the past, Clostridium difficile-associated disease (CDAD) was thought of mainly as a nosocomial disease associated with the use of broad-spectrum antibiotics, but its epidemiology seems to be ...
Scientists have characterised an emerging virulent strain of Clostridium difficile that has been associated with outbreaks of severe disease in North America and Europe. Their findings are published ...
Cases of potentially deadly diarrheal infections jumped by more than 200 percent in the nation’s hospitals between 2000 and 2005, fueling new worries about the next bad bug. Some 301,200 people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback